October 1-3, 2018
Hutton Hotel


Precision Medicine is facing significant barriers to broad acceptance and implementation.

Solutions must carefully consider the big picture and the practical realities of a complex, multi-stakeholder environment.

Leaders in this ecosystem currently do not have a combined forum to discuss and define the formation and growth of the Genetic Health Information Network.

An intimate meeting of influential leaders from across in the Genetic Health Information Network

Representing all stakeholders in this ecosystem, including
  • Health plans
  • Clinicians
  • Hospital systems
  • Researchers
  • Policy makers
  • Patients & Advocates
  • Laboratories
  • IT Vendors
  • Pharma

2018 Organizing Committee

Alphabetical order
Gil Alterovitz, MD

Director, Biomedical Cybernetics Laboratory

Harvard Medical School

Kristine Bordenave, MD

Corporate Medical Director


Carlos Bustamante, PhD

Chair, Department of Biomedical Data Science

Stanford University

Joshua Denny, MD

Professor of Biomedical Informatics and Medicine

Vanderbilt University

Henry Garlich

Director, Healthcare Value Solutions & Enhanced Clinical Programs

Blue Shield of California

Trent Haywood, MD

Chief Medical Officer

Blue Cross Blue Shield Association

Gillian Hooker, PhD, ScM, LCGC

VP, Clinical Development

Concert Genetics

Howard Levy, MD, PhD

Associate Professor of Medicine

Johns Hopkins Medicine

Matt Might, PHD

Director, Hugh Kaul Personalized Medicine Institute

University of Alabama at Birmingham

Robert Nussbaum, MD

Chief Medical Officer


Julie Ramage

National Accounts Director, Diagnostics


Benjamin Solomon, MD

Managing Director


The only multi-stakeholder gathering focused on solving the data, digital infrastructure, and economic challenges facing precision medicine

Intimate, carefully curated, invitation-only gathering

Full spectrum of stakeholders

Focused on needs and solutions

Collaborative, discussion-oriented format

Chatham-house rules — non-attribution

No vendors or marketing lists

Published conference summary and recommendations

Identify and resolve practical barriers facing precision medicine by

  • Improving the capture of clinical effectiveness and economic value data
  • Simplifying the test ordering and resulting workflow for clinicians, hospitals and labs
  • Streamlining the genetic test billing, adjudication and payment process
  • Reducing the frequency of misordered tests and surprise bills for patients
  • Empowering patients to harness the insights in their genetic makeup for greater health

2017 Speakers & Agenda

To view the 2017 Summit agenda, click here.
*2018 coming soon* 

Lee N. Newcomer, MD

SVP, Oncology and Genetics


Robert C. Green, MD, MPH

Director, Genomes2People

Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School

Suzanne Belinson, PhD, MPH

Executive Director

Blue Cross and Blue Shield Association

Mary E. Freivogel, MS, CGC


National Society of Genetic Counselors

Dan Roden, MD

Senior Vice President, Personalized Medicine

Vanderbilt University Medical Center

Nicole Boice

Founder & CEO

Global Genes

Dee Anna Smith


Sarah Cannon

Carlos Bustamante, PhD

Chair, Department of Biomedical Data Science

Stanford University

David McCallie, MD

SVP, Medical Informatics


Edward Abrahams, PhD


Personalized Medicine Coalition

Lisa Schlager

VP, Community Affairs & Public Policy

‎FORCE (Facing Our Risk of Cancer Empowered)

Taha Kass-Hout, MD

Former 1st Chief Health Informatics Officer

U.S. Food and Drug Administration (FDA)

Mara Aspinall


Health Catalysts

Robert Nussbaum, MD

Chief Medical Officer


+78 Net Promoter Score

This Summit is back by popular demand thanks to the enthusiastic response of last year’s participants.

“Intimate engagement with key stakeholders in the genomic medicine space that does not otherwise happen all that often…Excellent and efficient organization and moderation with summary of key points throughout.”

  • Director, Molecular Pathology

“Excellent speakers, panels, participants, and facilitation on relevant topics”

  • CEO, genomics company

“It was a unique and diverse group of stakeholders with (most importantly) time to interact with each other. Key gaps that need to be bridged were openly discussed and at least understood, if not resolved.”

  • Chief Medical Officer

“I thought that the summit raised important issues and brought together interested and diverse individuals to exchange ideas and propose serious solutions to real problems in the field.”

  • President, advocacy organization

“Open discussion, and a focus on actionable takeaways. Attendance by people who are influential.”

  • Director, Science Policy
This event is by invitation only. If you would like to nominate somebody, including yourself, to participate in the summit, please complete the following form: